Early study data from Wave Life Sciences suggests how editing RNA may yield viable medicines. Large and small drugmakers say ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Given this risk, we thought we'd take a look at whether CRISPR Therapeutics (NASDAQ:CRSP) shareholders should be worried ...

An editorial by Fyodor Urnov lays out the urgent case for major reform in the regulatory appraisal of clinical therapies involving CRISPR gene therapies.

An invited Guest Editorial entitled “Give Cas a Chance,” by Fyodor Urnov, PhD, Director of Technology & Translation at the ...

CRISPR technology allows for precise DNA modifications, holding promise for treating genetic disorders and revolutionizing ...

Editas, one of the oldest CRISPR-focused biotechs, is pivoting again — to a sickle cell treatment that requires editing a ...

What keeps some immune systems youthful and effective in warding off age-related diseases? A mouse study provides new ...

Have we entered the golden age of plant engineering?

The pharma market shows promise as gene therapy gains momentum through rapid advancements that address complex diseases and ...

Award from Highly Competitive Initiative Will Enable Ancilia to Advance Its Lead Program through IND Filing for Its First Clinical ...

EDT Cathie Wood’s ARK Investment bought 47.8K shares of Crispr Therapeutics (CRSP) today Published first on TheFly – the ...